Skip to main content
. 2022 Jun 28;10(7):1531. doi: 10.3390/biomedicines10071531

Figure 1.

Figure 1

Expression analysis of USP6NL in EGFRamp+/amp− in GBM samples. (A,B) mRNA level of EGFR and USP6NL in patients with GBM from The Cancer Genome Atlas (TCGA) dataset (n = 207) and corresponding healthy samples (n = 163). (C) Correlation analysis of mRNA expression of EGFR and USP6NL in the TCGA-GBM database. (D) Immunohistochemistry analysis of USP6NL expression in EGFR-amplified samples compared with their nonamplified SHH-GBM cohort (n = 60) (original magnification ×100). (E) Protein and (F) mRNA levels of USP6NL in four (U87MG, T98G, Hs683, and DBTRG05MG) GBM cell lines were assessed using Western blot and RT-PCR methods, respectively. *** p < 0.001, ** p < 0.01, * p < 0.05.